BioCentury | Jan 13, 2018
Finance

Choosy investors

...NASDAQ:CPRX) 11/28/17 $57.5 $358.7 $400.7 12% Sosei Group Corp. (Tokyo:4565) 11/22/17 $199.0 $1,831.1 $1,854.8 1% BioPharmX Corp....
BioCentury | May 2, 2017
Financial News

BioPharmX completes $5M registered direct offering

...Dermatology company BioPharmX Corp. (NYSE-M:BPMX) raised $5 million through the sale of 6.4 million shares at $0.78...
...warrants to purchase up to 3.2 million shares at $0.90. BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Chris Lieu BioPharmX Corp....
BioCentury | Jan 6, 2017
Finance

Good riddance

...NASDAQ:CLRB) 11/23/16 $9.2 $10.5 $8.5 -19% Tracon Pharmaceuticals Inc. (NASDAQ:TCON) 11/23/16 $17.4 $92.5 $78.8 -15% BioPharmX Corp....
BioCentury | Jan 5, 2017
Clinical News

BPX-01: Completed Ph II enrollment

...about 1 g of 1% or 2% BPX-01 topical gel once daily for 12 weeks. BioPharmX Corp....
...IGA) at 12 weeks Status: Completed Phase IIb enrollment Milestone: Phase IIb data (1H17) Jaime De Leon BPX-01 BioPharmX Corp....
BioCentury | Dec 1, 2016
Financial News

BioPharmX completes follow-on

...up to 2,143 shares. Each preferred share converts at $0.35. BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Alex Himes BioPharmX Corp....
BioCentury | Oct 24, 2016
Financial News

BioPharmX proposes follow-on

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Business: Drug delivery, Dermatology, Neurology Date announced: 2016-10-14 Type: Follow-on To be raised: Up to $8 million Shares: TBD Price prior: $0.34 Underwriter: Roth Capital Partners Note: Investors will...
BioCentury | Oct 3, 2016
Financial News

BioPharmX completes direct public offering

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Business: Drug delivery, Dermatology, Neurology Date completed: 2016-09-26 Type: Direct public offering Raised: $930,000 Shares: 1.6 million Price: $0.60 Shares after offering: 32.7 million Placement agent: H.C. Wainwright Investor:...
BioCentury | Oct 3, 2016
Financial News

BioPharmX completes direct public offering

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Business: Drug delivery, Dermatology, Neurology Date completed: 2016-09-26 Type: Direct public offering Raised: $930,000 Shares: 1.6 million Price: $0.60 Shares after offering: 32.7 million Placement agent: H.C. Wainwright Investor:...
BioCentury | Sep 5, 2016
Clinical News

BPX-01: Phase IIa final data

...mean P. acnes bacteria from baseline to week 4 by 90.9% vs. 65.3% for vehicle. BioPharmX...
...from the Phase IIb OPAL trial of BPX-01 to treat acne are expected in 1H17. BioPharmX Corp....
BioCentury | Sep 5, 2016
Clinical News

BPX-01: Phase IIb started

...for 12 weeks in about 225 patients with moderate to severe inflammatory, non-nodular acne vulgaris. BioPharmX Corp....
Items per page:
1 - 10 of 22
BioCentury | Jan 13, 2018
Finance

Choosy investors

...NASDAQ:CPRX) 11/28/17 $57.5 $358.7 $400.7 12% Sosei Group Corp. (Tokyo:4565) 11/22/17 $199.0 $1,831.1 $1,854.8 1% BioPharmX Corp....
BioCentury | May 2, 2017
Financial News

BioPharmX completes $5M registered direct offering

...Dermatology company BioPharmX Corp. (NYSE-M:BPMX) raised $5 million through the sale of 6.4 million shares at $0.78...
...warrants to purchase up to 3.2 million shares at $0.90. BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Chris Lieu BioPharmX Corp....
BioCentury | Jan 6, 2017
Finance

Good riddance

...NASDAQ:CLRB) 11/23/16 $9.2 $10.5 $8.5 -19% Tracon Pharmaceuticals Inc. (NASDAQ:TCON) 11/23/16 $17.4 $92.5 $78.8 -15% BioPharmX Corp....
BioCentury | Jan 5, 2017
Clinical News

BPX-01: Completed Ph II enrollment

...about 1 g of 1% or 2% BPX-01 topical gel once daily for 12 weeks. BioPharmX Corp....
...IGA) at 12 weeks Status: Completed Phase IIb enrollment Milestone: Phase IIb data (1H17) Jaime De Leon BPX-01 BioPharmX Corp....
BioCentury | Dec 1, 2016
Financial News

BioPharmX completes follow-on

...up to 2,143 shares. Each preferred share converts at $0.35. BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Alex Himes BioPharmX Corp....
BioCentury | Oct 24, 2016
Financial News

BioPharmX proposes follow-on

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Business: Drug delivery, Dermatology, Neurology Date announced: 2016-10-14 Type: Follow-on To be raised: Up to $8 million Shares: TBD Price prior: $0.34 Underwriter: Roth Capital Partners Note: Investors will...
BioCentury | Oct 3, 2016
Financial News

BioPharmX completes direct public offering

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Business: Drug delivery, Dermatology, Neurology Date completed: 2016-09-26 Type: Direct public offering Raised: $930,000 Shares: 1.6 million Price: $0.60 Shares after offering: 32.7 million Placement agent: H.C. Wainwright Investor:...
BioCentury | Oct 3, 2016
Financial News

BioPharmX completes direct public offering

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif. Business: Drug delivery, Dermatology, Neurology Date completed: 2016-09-26 Type: Direct public offering Raised: $930,000 Shares: 1.6 million Price: $0.60 Shares after offering: 32.7 million Placement agent: H.C. Wainwright Investor:...
BioCentury | Sep 5, 2016
Clinical News

BPX-01: Phase IIa final data

...mean P. acnes bacteria from baseline to week 4 by 90.9% vs. 65.3% for vehicle. BioPharmX...
...from the Phase IIb OPAL trial of BPX-01 to treat acne are expected in 1H17. BioPharmX Corp....
BioCentury | Sep 5, 2016
Clinical News

BPX-01: Phase IIb started

...for 12 weeks in about 225 patients with moderate to severe inflammatory, non-nodular acne vulgaris. BioPharmX Corp....
Items per page:
1 - 10 of 22